PhD Student
Humanitas Clinical and Research Hospital, Italy
Luca Tiraboschi achieved his bachelor’s degree in Biological Science and his Master’s degree in Biology at the “Università degli Studi di Milano – Bicocca” in 2017 and 2020 respectively. During his academic path he delved the fields of oncologic research, chemotherapeutics’ pharmacology, and cancer immunology. During the internship at the IRCCS Humanitas Clinical and Research Hospital (2019-2020) in the laboratory of Mucosal Immunology and Microbiota directed by Prof. Rescigno he was involved in the preclinical research for the generation of a universal anticancer vaccine. He is still collaborating at this project which produced significant results (Melacarne et al., 2021) also in veterinarian clinical trials (Marconato et al., 2022 and 2023). He is member of the UNICANVAX consortium funded by AIRC 5X100 (Prof. Rescigno, 2019) aimed at translating into the clinic the vaccine to treat metastatic melanoma and sarcoma patients. In 2021 he has been enrolled in the Humanitas University’s PhD program in Molecular and Experimental Medicine in Prof. Rescigno’s lab where he was involved also in other relevant projects aimed at investigating cancer-microbiota-immune relationships (Ferrari et at., 2023). His PhD project explores the composition of intratumoral microbiota in the context of soft tissue sarcoma and its relevance for chemotherapeutic outcome. In 2022 he achieved the AIRC pre-doc fellowship to continue his study.
